Medco, SureGene to Validate SULT4A1 Variants for Gauging Patient Response to Antipsychotic Drugs | GenomeWeb

By Turna Ray

Medco is expanding its personalized medicine research efforts into antipsychotic drugs, a highly variable class of therapies to which industry and academic researchers are increasingly applying pharmacogenomic strategies.

Medco Research Institute announced this week that it will work with SureGene to investigate genetic variations that may be used to administer antipsychotic drugs to patients most likely to respond to them.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.